Intact Genomics

Intact Genomics (IG®) is an ISO 13485:2016 certified biotech company that provides high-quality life science products and advanced genomic services to customers worldwide. We provide life science products for isothermal amplification, gene-editing, simplified molecular cloning and transformation, large DNA fragment cloning and metagenomics. Customer satisfaction is our top priority. Whether you have questions about product selection, protocols, or troubleshooting, our dedicated support team is here to assist you. We offer customization options for most of our products to meet your specific requirements. All our products are developed, manufactured, and shipped from our facility in St. Louis, Missouri, USA.

Browse Intact Genomics Products

AGL1 (pSoup) Agrobacterium ElectroCompetent Cells

SKU: 1283PS-12|Size: 6x 50 µL

AGL1 (pSoup) ElectroCompetent Agrobacterium

SKU: 1283PS-36|Size: 50 µL

AGL1 Agrobacterium Chemically Competent Cells

SKU: 1083-06|Size: 6x 50 µL

AGL1 Agrobacterium ElectroCompetent Cells

SKU: 1283-12|Size: 6x 50 µL

ATCC15834 Agrobacterium Chemically Competent Cells

SKU: 1075-18|Size: 18x 50 µL

ATCC15834 Agrobacterium ElectroCompetent Cells

SKU: 1275-36|Size: 18x 50 µL

ATCC15834 Chemically Competent Agrobacterium

SKU: 1075-12|Size: 6x 50 µL

Agrobacterium Chemically Competent Cells Combo Pack

SKU: 1091-12|Size: 12x 50 µL

Agrobacterium ElectroCompetent Cells Combo Pack

SKU: 1290-24|Size: 12x 50 µL

Ar. A4 ElectroCompetent Agrobacterium

SKU: 1272-18|Size: 18x 50 µL

Ar. Qual ElectroCompetent Agrobacterium

SKU: 1273-18|Size: 18x 50 µL

Ar.A4 Agrobacterium Chemically Competent Cells

SKU: 1072-06|Size: 6x 50 µL

Ar.A4 Agrobacterium ElectroCompetent Cells

SKU: 1272-12|Size: 6x 50 µL

Ar.Qual Chemically Competent Agrobacterium

SKU: 1073-18|Size: 50 µL

Ar.Qual ElectroCompetent Agrobacterium

SKU: 1273-12|Size: 6x 50 µL

BL21 (DE3) Chemically Competent Cells

SKU: 1051-12|Size: 12x 50 µL

BL21 (DE3) Electrocompetent Cells

SKU: 1254-48|Size: 12x 100 µL

BL21 (DE3) pLysS Chemically Competent Cells

SKU: 1056-12|Size: 12x 50 µL

BL21 (DE3) pLysS ElectroCompetent Cells

SKU: 1256-24|Size: 6x 100 μL

BL21 Chemically Competent Cells

SKU: 1041-24|Size: 24x 50 µL

BL21(DE3) Chemically Competent Cells - 12x200µl

SKU: 1054-48|Size: 12/PK

Bsu DNA Polymerase Large Fragment

SKU: 3582|Size: 200 Units - 5 Units/µL

Bsu DNA Polymerase Large Fragment, Glycerol Free

SKU: 3585GF|Size: 1000 Units - 5 Units/µL

Bsu DNA Polymerase Large Fragment, Lyophilized

SKU: 3582Lyo|Size: 200 Units - 5 Units/µL

C58C1 Agrobacterium Chemically Competent Cells

SKU: 1086-06|Size: 6x 50 µL

C58C1 Agrobacterium ElectroCompetent Cells

SKU: 1286-36|Size: 18x 50 µL

Cas12a Nuclease

SKU: 3376|Size: 400 µg - 1600 ng/µL

Cas9 Nuclease

SKU: 3276|Size: 400 µg - 1600 ng/µL - 2500 pmol

DH10B Chemically Competent Cells

SKU: 1012-48|Size: 24x 100 µL

DH5-Alpha Chemically Competent Cells

SKU: 1032-48|Size: 24x 100 µL

DL39 (DE3) Chemically Competent Cells - 24x50µl

SKU: 1061-24|Size: 24/PK

DL39 (DE3) Chemically Competent Cells - 6x200µl

SKU: 1064-24|Size: 200 µL

DNA Polymerase I, Large (Klenow) Fragment - 1,000 units

SKU: 3262|Size: 1/EA

DirectPlate XL™ DH10B Chemically Competent Cells

SKU: 1094-36|Size: 36x 50 µL

DirectPlate® 10B Chemically Competent Cells

SKU: 1015-12|Size: 12x 50 µL

DirectPlate® BL21 (DE3) Chemically Competent Cells

SKU: 1019-36|Size: 36x 50 µL

DirectPlate® DH5-alpha Chemically Competent Cells

SKU: 1013-12|Size: 12x 50 µL

DirectPlate® TG1 Phage Display Chemically Competent Cells

SKU: 1024-36|Size: 36x 50 µL

E. coli DNA Polymerase I (Pol I) - 2,500 units

SKU: 3268|Size: 1/EA

EHA105 (pSoup) Agrobacterium ElectroCompetent Cells

SKU: 1284PS-12|Size: 6x 50 µL

EHA105 Agrobacterium Chemically Competent Cells

SKU: 1084-10|Size: 10x 50 µL

EHA105 Agrobacterium ElectroCompetent Cells

SKU: 1284-20|Size: 10x 50 µL

Endonuclease IV (Nfo)

SKU: 3425|Size: 5000 Units - 10 Units/µL

Exonuclease III

SKU: 3415|Size: 25000 Units - 100 Units/µL

FastAmp® Plant Cell Lysis Solution

SKU: 4611|Size: 20 mL

FastAmp® Plant Direct PCR Kit

SKU: 4612|Size: 250 Reactions

FastAmp® Plant Direct RPA Kit

SKU: 3621|Size: 25 Reactions

FastAmp® Viral and Cell Lysis Solution

SKU: 4633|Size: 500 Reactions - 250 mL

FastAmp® qRPA SYBR Kit

SKU: 3611|Size: 25 Reactions

GV3101 (pSoup) Agrobacterium ElectroCompetent Cells

SKU: 1282PS-36|Size: 18x 50 µL

GV3101 (pSoup-19) Agrobacterium ElectroCompetent Cells

SKU: 1282PS19-36|Size: 18x 50 µL

GV3101 Agrobacterium Chemically Competent Cells

SKU: 1082-18|Size: 18x 50 µL

GV3101 Agrobacterium ElectroCompetent Cells

SKU: 1282-36|Size: 18x 50 µL

Glycerol Free T4 gp32 Protein

SKU: 3514GF|Size: 250 µg - 10 µg/µL

HB101 Chemically Competent Cells

SKU: 1071-24|Size: 24x 100 µL

HB101 Electrocompetent Cells

SKU: 1271-48|Size: 24x 50 μL

Hot Start Taq 2x Master Mix

SKU: 3296|Size: 500 Reactions - 50 μL Reaction Volume

Hot Start Taq DNA Polymerase - 1000 units

SKU: 3293|Size: 1000 Units

Hot Start Taq DNA Polymerase - 1000 units with seperate dNTP mix

SKU: 3293d|Size: 1000 units with seperate dNTP mix

I7® High-Fidelity DNA Polymerase

SKU: 3254|Size: 200 Units

I7® High-Fidelity DNA Polymerase 2X Master Mix

SKU: 3259|Size: 500 Reactions

IG® Autoinduction DE3 Chemically Competent Cells

SKU: 1065-06|Size: 6x 50 µL

IG® Autoinduction DE3 ElectroCompetent Cells

SKU: 1265-12|Size: 6x 50 µL

IG® Autoinduction Medium

SKU: 1722-1L|Size: 1 L

IG® RPA Master Mix

SKU: 3545|Size: 25 Reactions

Ig-Fusion™ Cloning Enzyme Premix

SKU: 4111-1|Size: 10 Reactions

Ig-Fusion™ Cloning Kit

SKU: 4111|Size: 10 Reactions

IgMax™ DH10B ElectroCompetent Cells

SKU: 1284-24|Size: 6x 100 µL

IgScript™ First Strand cDNA Synthesis Kit

SKU: 4314|Size: 100 Reactions

IgScript™ Glycerol-free Reverse Transcriptase

SKU: 3342GF|Size: 10000 Units - 200 U/µL

IgScript™ One Step RT-PCR Kit

SKU: 4211|Size: 100 Reactions - 20 µL Reaction Volume

IgScript™ One Step RT-qPCR Kit

SKU: 4218|Size: 500 Reactions - 20 µL Reaction Volume

IgScript™ Probe-Based One Step RT-qPCR Kit

SKU: 4212|Size: 200 Reactions - 20 µL Reaction Volume

IgScript™ Probe-Based RT-qPCR Kit

SKU: 4245|Size: 100 Reactions - 20 µL Reaction Volume

IgScript™ Probe-Based qPCR master mix

SKU: 4235|Size: 1000 Reactions - 20 µL Reaction Volume

IgScript™ Reverse Transcriptase

SKU: 3344|Size: 50000 Units - 200 U/µL

Ig® 10B Chemically Competent Cells (High Efficiency)

SKU: 1012-12|Size: 6x 100 µL

Ig® 10B Electrocompetent Cells

SKU: 1214-48|Size: 12x 100 µL

Ig® 5-alpha Chemically Competent Cells (High Efficiency)

SKU: 1032-24|Size: 12x 100 µL

Ig® 5-alpha Electrocompetent Cells

SKU: 1234-48|Size: 12x 100 µL

Ig® ER2738 Phage Display ElectroCompetent Cells

SKU: 1217-24|Size: 6x 100 µL

Ig® Recombinase Polymerase Amplification (RPA) Kit v1

SKU: 3526|Size: 25 Reactions

Ig® Recombinase Polymerase Amplification (RPA) Kit v2

SKU: 3530|Size: 100 Reactions

Ig® Recombinase Polymerase Amplification (RPA) Kit v3

SKU: 3531|Size: 500 Reactions

Ig® Recombinase Polymerase Amplification (RPA) Kit v4

SKU: 3536|Size: 500 Reactions

Ig® SYBR Green qPCR 2X Master Mix

SKU: 3356|Size: 500 Reactions - 10x 500 µL

Ig® Stable 2 Chemically Competent Cells

SKU: 1016-24|Size: 24x 50 μL

Ig® Stable 2 Electrocompetent E. coli Cells

SKU: 1216-24|Size: 12x 50 μL

Ig® XL1 Blue Max Chemically Competent Cells

SKU: 1023-24|Size: 24x 50 µL

Ig® XL1 Blue Max ElectroCompetent Cells

SKU: 1223-12|Size: 6x 50 µL

Ig® ccdB Resist™ Chemically Competent Cells

SKU: 1069-12|Size: 12x 50 μL

Ig® ccdB Resist™ Electrocompetent E. coli Cells

SKU: 1269-24|Size: 12x 50 μL

Ig® ER2738 Phage Display Chemically Competent Cells

SKU: 1007-12|Size: 12x 50 μL

JM109 (DE3) Chemically Competent Cells

SKU: 1063-48|Size: 12x 200 µL

JM109 Chemically Competent Cells

SKU: 1062-48|Size: 12x 200 µL

K599 Agrobacterium Chemically Competent Cells

SKU: 1087-18|Size: 18x 50 µL

K599 Agrobacterium ElectroCompetent Cells

SKU: 1287-36|Size: 18x 50 µL

LBA4404 Agrobacterium Chemically Competent Cells

SKU: 1085-18|Size: 18x 50 µL

LBA4404 Agrobacterium ElectroCompetent Cells

SKU: 1285-20|Size: 10x 50 µL

MG1655 Chemically Competent Cells

SKU: 1076-12|Size: 12x 50 µL

Competent cells

Hot products

GV3101 Agrobacterium Chemically Competent Cells

SKU: 1082-06|Size: 6x 50 µL

EHA105 Agrobacterium Chemically Competent Cells

SKU: 1084-06|Size: 6x 50 µL

AGL1 Agrobacterium ElectroCompetent Cells

SKU: 1283-12|Size: 6x 50 µL

EHA105 Agrobacterium ElectroCompetent Cells

SKU: 1284-12|Size: 6x 50 µL

LBA4404 Agrobacterium Chemically Competent Cells

SKU: 1085-06|Size: 6x 50 µL

LBA4404 Agrobacterium ElectroCompetent Cells

SKU: 1285-12|Size: 6x 50 µL

Enzymes:

Hot Products

T4 gp32 Protein

SKU: 3516|Size: 500 µg - 10 µg/µL

T4 gp32 Protein

SKU: 3513|Size: 250 µg - 10 µg/µL

T7 Endonuclease I

SKU: 3612|Size: 1250 Units

T4 UvsX DNA Recombinase

SKU: 3562|Size: 100 µg - 5 μg/μL

T4 UvsX DNA Recombinase, Glycerol Free

SKU: 3562GF|Size: 100 µg - 5 μg/μL

Bsu DNA Polymerase Large Fragment

SKU: 3582|Size: 200 Units - 5 Units/µL

Reverse Transcription Enzymes and Kits

Hot products

Glycerol Free T4 gp32 Protein

SKU: 3514GF|Size: 250 µg - 10 µg/µL

IgScript™ One Step RT-PCR Kit

SKU: 4211|Size: 100 Reactions - 20 µL Reaction Volume

IgScript™ Probe-Based One Step RT-qPCR Kit

SKU: 4212|Size: 200 Reactions - 20 µL Reaction Volume

CRISPR Gene-Editing enzymes and Tools

Hot products

PEmax Enzyme

SKU: 3473|Size: 80 µg

SgRNA Synthesis Kit for Cas9 Nuclease

SKU: 3203|Size: 10 Reactions - 20 µL Reaction Volume

T5 Exonuclease

SKU: 3374|Size: 5000 Units

Resources & Documents

File 1

PDF preview will load when visible...

Recent Breakthroughs

Metabolomic insights into Lyme neuroborreliosis: Exploring cerebrospinal fluid for diagnostic clues.

Kuukkanen I, Pietikäinen A, Rissanen T, Hurme S, Kortela E, Hytönen J, Karonen M.

Ticks Tick Borne Dis

PMID:42001681

Free PMC article

Lyme neuroborreliosis (LNB), a disseminated manifestation of Lyme borreliosis (LB), arises when Borrelia burgdorferi sensu lato (Bbsl) spirochetes disseminate within the host and damage the peripheral nervous system and meninges, and in rare cases, also the parenchyma of the central nervous system (CNS). While early-stage LB is diagnosed clinically, accurate diagnosis of LNB requires cerebrospinal fluid (CSF) analysis, demonstrating pleocytosis and intrathecal synthesis of Bbsl-specific antibodies. There are, however, limitations in current LNB diagnostics, such as the unspecific nature of pleocytosis and post-treatment persistence of intrathecal antibodies necessitating the search for novel biomarkers. In this study, we employed untargeted ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) to profile small metabolites (<1500 Da) in CSF samples from subjects with definite acute LNB. Comparative analyses of metabolite profiles were performed between pretreatment subject samples (n = 63) and the following groups: (A) a subset of samples collected three weeks after treatment initiation from the same individuals (n = 36), (B) Bbsl antibody-negative subjects (non-LNB, n = 61), (C) subjects with other CNS infections (n = 21). Additionally, pretreatment LNB samples were compared between individuals with radiculitis (n = 40) and those without radiculitis (n = 23) (D). Out of 4222 molecular features (MFs) detected, 131 were prioritized based on statistical significance and magnitude of change for further detailed structural characterization. Altered metabolite classes included compounds from lysophospholipids [e.g., lysophosphatidylcholine (16:0), and lysophosphatidylethanolamine (18:0)], sphingomyelins [e.g., sphingomyelin (d18:1/14:0) and sphingomyelin d16:1/16:0)], sphingoid bases (e.g., d19:0 sphinganine, and 3-ketosphingosine), fatty acid amides (e.g., palmitoleamide and oleamide), cyclic phosphatidic acids [i.e., cyclic phosphatidic acid (16:0) and cyclic phosphatidic acid (18:2)], and amino acid metabolism (i.e., DL-glutamine, 5-hydroxytryptophan and DL-kynurenine). These findings underscore the potential of CSF metabolomics as a powerful complementary tool for diagnosing LNB and differentiating it from other CNS conditions. The identified metabolic signatures offer a foundation for future biomarker development and may enhance diagnostic precision, guide treatment strategies, and deepen our understanding of LNB pathogenesis.

Isotope Dilution NanoLC-MS/MS Quantitation of Methylglyoxal DNA-Protein Cross-Links: Formation and Repair in Human Cells.

Omondi RO, Barnes EM, Gurajala KC, Fisette G, Chaudray IA, Erber L.

Anal Chem

PMID:41995195

Free PMC article

DNA-protein cross-links (DPCs) represent a prevalent form of DNA damage that forms when cellular proteins become covalently trapped to DNA strands upon exposure to various endogenous and exogenous agents. Methylglyoxal is an endogenous metabolite that reacts with guanine and adenine bases in DNA and RNA, as well as cysteine, arginine, and lysine residues in proteins, generating advanced glycation end-products (AGEs), including DPCs. These modifications have been linked to human disease, including cancer, liver disease, diabetes, and neurodegenerative disorders. Herein, we present a mass spectrometry method for quantifying MGO-induced DNA-protein cross-links (DPCs) in human cells. We prepared an isotope 15 N 2 13 C 6 -dG-MGO-Lys internal standard and developed a quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for detecting and quantifying the formation and repair of dG-MGO-Lys DPCs in cells. Genomic DNA was extracted, subjected to sequential protease and nuclease digestion, purified by offline high-performance liquid chromatography (HPLC), and analyzed by LC-MS/MS. The method's standard curve showed a strong linear relationship across a concentration range of 10-1000 fmol ( R 2 = 0.9994). The method achieved limits of detection (LOD) and quantification (LOQ) of 10 and 20 fmol, respectively. Inhibition of proteasome and SPRTN activity revealed that SPRTN functions as a predominant proteolytic enzyme in MGO DPC repair. Overall, this analytical approach can offer valuable insights into the relevance of DPCs in diseases linked to elevated MGO levels.

Label-Free High-Throughput Screening of CYP3A4 Inhibitors Using Acoustic Ejection Mass Spectrometry.

Rimmer MA, Wang J, Ranathunge TA, Shi Z, Li Y, Lee D, Chai SC, Lin W, Twarog NR, Ansari AZ, Shelat AA, Young BM, Chen T, Yang L.

Anal Chem

PMID:41997578

Free PMC article

Label-free high-throughput screening (HTS) technologies have greatly accelerated early drug discovery by allowing direct measurement of biochemical activity without the need for chemical labels. Techniques like MALDI-TOF, RapidFire, desorption electrospray ionization, and acoustic-mist ionization mass spectrometry have shown strong analytical performance. More recently, acoustic droplet ejection mass spectrometry (AEMS) has emerged as a next-generation platform capable of analyzing over a thousand data points per hour. In this study, we thoroughly evaluated an AEMS workflow using cytochrome P450 3A4 (CYP3A4) as a model enzyme. Screening a library of 9702 compounds, this work represents the first successful label-free HTS campaign for CYP3A4 inhibitors in a 384-well format using AEMS. The result using nifedipine as a substrate was comparable to the widely used P450-Glo luminescence assay but with fewer inhibitor hits identifications. To further compare and parse differences between the methods and the substrates, 819 hits were retested using AEMS with luciferin isopropyl acetal, the same substrate used in the luminescence assay. The findings confirmed that both the assay method and the substrate influence which inhibitors were detected. Overall, this study established AEMS as a robust and reliable tool for CYP3A4 inhibitor screening. It offers high analytical precision, fewer false positives, compatibility with multiple substrates, and direct detection of metabolites, providing a practical way to validate hits and improve confidence in early drug discovery efforts.

Quantification of the Active Metabolites 4-Methylaminoantipyrine and 4-Aminoantipyrine of Dipyrone From Human Plasma by LC-MS/MS.

Schmidt S, Ihmsen H, Golditz T, Schüttler J, Wehrfritz A.

Int J Anal Chem

PMID:42004449

Free PMC article

Dipyrone (metamizole) is widely used as a nonopioid analgesic in perioperative and intensive care settings; however, its administration may be associated with severe adverse effects. In this study, we describe an analytical assay for the quantification of the active metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS). In addition, the protein-unbound fractions of both metabolites were determined by ultrafiltration. Chromatographic separation was performed on a UPLC system using gradient elution, followed by MS/MS detection with an electrospray ionization source. The limits of detection for both metabolites were 100 ng/mL. Across the investigated concentration range (100-10,000 ng/mL), the relative error (%RE) ranged from -6.3% to +3.5%. Intra-day and inter-assay variability were below 10%. Method validation was conducted in accordance with the 2018 FDA Bioanalytical Method Validation Guidance, and all evaluated parameters met the required criteria for analytical accuracy and precision. The developed assay is suitable for monitoring dipyrone metabolites and may support the prevention of potential overdosing during prolonged analgesic therapy or in intensive care settings.

Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors.

Brattås MK, Hatfield KJ, Paulsen Rye K, Reikvam H.

Metabolomics

PMID:41995902

Free PMC article

Introduction Acute myelogenous leukemia (AML) is a heterogeneous hematological malignancy. Despite therapeutic advances, high relapse rates and poor survival persist, underscoring the need for new treatment strategies. Spleen tyrosine kinase (SYK) is crucial for leukemic cell survival and proliferation, and SYK inhibition is being explored in AML therapy. Objective This study aimed to identify whether distinct baseline serum metabolic profiles can differentiate between AML patient samples exhibiting high versus low in vitro sensitivity to SYK inhibition. Methods Leukemic cells from 49 AML patients were evaluated for their in vitro antiproliferative response to SYK-selective inhibitors (entospletinib, RO9021) and dual SYK/FLT3 inhibitors (fostamatinib, TAK-659). Serum samples from the same patients were subjected to untargeted metabolomic profiling using liquid chromatography-mass spectrometry (LC-MS). Bioinformatic analyses were applied to identify metabolic signatures associated with differential drug sensitivity. Results Hierarchical clustering identified three drug sensitivity groups, i.e. high, intermediate, low. Untargeted metabolomics identified 1204 metabolites across major pathways. Comparative analyses revealed distinct metabolic differences between patients with high versus low sensitivity to SYK inhibitors. For dual SYK/FLT3 inhibitors, lipid metabolites consistently were more discriminative for drug response, while for SYK selective inhibitors the profiles were more heterogeneous. Pathway analyses highlighted alterations in amino acid, lipid, and xenobiotic metabolism, including arginine biosynthesis and glycine/serine metabolism, as potential determinators for effect of SYK inhibition. Conclusion This study highlights potential metabolite signatures associated with in vitro SYK-targeted therapy in AML. These findings support future research to identify potential serum biomarkers, guiding personalized SYK inhibition strategies in AML.